Why the study?
RFCA for ventricular arrhythmia can encounter limitations from deep intramural foci or proximity to coronary arteries, which retrograde coronary venous ethanol ablation may address.
Retrograde coronary venous ethanol ablation may be a feasible strategy for addressing anatomic challenges in ventricular tachycardia ablation in patients with hypertrophic cardiomyopathy.
RCVEA may address RFCA limitations in select VA; single case leaves open safety and efficacy questions.
Radiofrequency catheter ablation (RFCA) has become the standard therapy for ventricular arrhythmia (VA).1 Despite the relatively high effectiveness, RFCA, even when utilizing combined endocardial and epicardial approaches, may encounter limitations, often owing to anatomic challenges such as deep intramural arrhythmogenic foci or proximity to the coronary arteries.2 Recently, several studies have demonstrated that retrograde coronary venous ethanol ablation (RCVEA) is a promising strategy for addressing these challenges, with high acute success rates and low complication rates.
No takes yet. Share an insight, caveat, or question.
Iwakawa et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: